Waystar Considers Sale Amid Market Challenges, Sources Reveal

Waystar, a prominent healthcare software company, is reportedly exploring strategic options, including a potential sale, according to sources familiar with the situation. This move comes two years after the company went public on the New York Stock Exchange.

Exploration of Strategic Options

Based in Lehi, Utah, and Louisville, Kentucky, Waystar has enlisted the services of investment bank Evercore to advise on the process. The discussions, still in preliminary stages, may not necessarily result in a sale, sources caution. The company, which specializes in technology solutions for automating and managing healthcare administrative tasks, aims to capitalize on the higher valuations typically afforded to tech firms over service-oriented businesses.

Waystar has not commented on these developments, and Evercore has yet to respond to inquiries regarding their involvement. The firm's market value has taken a hit, dropping to approximately $4.8 billion following a 24% decline in its share price this year, mirroring a broader downturn in the software sector.

Market Dynamics and Investor Sentiment

The potential sale could serve as a litmus test for investor interest in software companies amid fluctuating market conditions. Initially, Waystar's positioning as a tech company was well-received, with shares soaring from $20 to a peak of $45 in 2025. However, concerns about the impact of artificial intelligence on the software industry have since dampened investor enthusiasm, as noted by a Morgan Stanley report in July.

Waystar originated from the 2017 merger of Zirmed and Navicure, two healthcare revenue management entities. Major stakeholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, who took the company public in 2024. EQT remains the largest shareholder with a 13% stake, followed by CPPIB at 10% and BlackRock Institutional Trust Company at 8%, according to data from LSEG.

Investor Reactions and Future Prospects

EQT and BlackRock have declined to comment on the potential sale, while CPPIB has not provided a response. The exploration of a sale suggests Waystar’s management is seeking to navigate the current market challenges by potentially returning to private ownership, thereby offering flexibility in strategic decision-making.

The outcome of this process remains uncertain, but it highlights the pressures faced by healthcare technology companies in adapting to rapid technological changes and investor expectations. As the situation develops, industry observers will be keenly watching for any further announcements regarding Waystar’s future direction.